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Lactococcus lactis is a promising candidate for the development of mucosal vaccines.
More than 20 years of experimental research supports this immunization approach. In
addition, 3′ 5′- cyclic di-adenosine monophosphate (c-di-AMP) is a bacterial second
messenger that plays a key role in the regulation of diverse physiological functions
(potassium and cellular wall homeostasis, among others). Moreover, recent studies
showed that c-di-AMP has a strong mucosal adjuvant activity that promotes both
humoral and cellular immune responses. In this study, we report the development of
a novel mucosal vaccine prototype based on a genetically engineered L. lactis strain.
First, we demonstrate that homologous expression of cdaA gen in L. lactis is able to
increase c-di-AMP levels. Thus, we hypothesized that in vivo synthesis of the adjuvant
can be combined with production of an antigen of interest in a separate form or jointly
in the same strain. Therefore, a specifically designed fragment of the trans-sialidase
(TScf) enzyme from the Trypanosoma cruzi parasite, the etiological agent of Chagas
disease, was selected to evaluate as proof of concept the immune response triggered
by our vaccine prototypes. Consequently, we found that oral administration of a L. lactis
strain expressing antigenic TScf combined with another L. lactis strain producing the
adjuvant c-di-AMP could elicit a TS-specific immune response. Also, an additional
L. lactis strain containing a single plasmid with both cdaA and tscf genes under the Pcit
and Pnis promoters, respectively, was also able to elicit a specific immune response.
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Thus, the current report is the first one to describe an engineered L. lactis strain that
simultaneously synthesizes the adjuvant c-di-AMP as well as a heterologous antigen
in order to develop a simple and economical system for the formulation of vaccine
prototypes using a food grade lactic acid bacterium.
Keywords: Lactococcus lactis, c-di-AMP adjuvant, live vaccine, delivery system, T. cruzi, trans-sialidase
INTRODUCTION
Lactococcus lactis is one of the most frequently used
microorganisms in the food industry across the world (de
Vos, 2011; Smid and Kleerebezem, 2014). Moreover, recent
reports that use L. lactis as a therapeutic agent for the treatment
of different human and animal diseases have stimulated
the interest of this microorganism by the pharmaceutical
industry. The potential biotechnological applications of this
microorganism in the pharmaceutical drug production and the
spectrum of possibilities it offers constitutes nowadays one of the
most striking reasons for the investigation on L. lactis genetic
manipulation (Cano-Garrido et al., 2015). In particular, the use of
L. lactis as a live non-invasive mucosal vaccine seems a promising
alternative due to their GRAS (Generally Recognized As Safe)
status (Miyoshi et al., 2002; Bermudez-Humaran et al., 2003;
Foligne et al., 2007; Wells and Mercenier, 2008; Cano-Garrido
et al., 2015; Kim et al., 2015; Mancha-Agresti et al., 2017).
L. lactis has been successfully employed to produce specific
viral and bacterial antigens to cope infections or non-antigenic
immunomodulatory proteins like cytokines or proteases to
control infections or more complex inflammatory diseases
such as the inflammatory bowel disease (Miyoshi et al., 2002;
Bermudez-Humaran et al., 2003; Foligne et al., 2007; Wells and
Mercenier, 2008; Marelli et al., 2011; Cano-Garrido et al., 2015;
Kim et al., 2015; Mancha-Agresti et al., 2017). Most importantly,
it has been used for the expression and delivery of heterologous
antigens to develop oral and mucosal vaccines (Wells and
Mercenier, 2008; Cano-Garrido et al., 2015).
On the other hand, a key factor for the development of
human subunit vaccines is to define not only a suitable antigen
but also an adequate adjuvant. Vaccine adjuvant categories are
classically based on the underlying mechanism of action. In this
regard, they may be divided into delivery systems (or particulate
adjuvants) and immune potentiators (or immune stimulators)
(Pashine et al., 2005; Wells and Mercenier, 2008). Moreover, both
types of adjuvants can act as mucosal adjuvants (Apostolico et al.,
2016).
In the last decade, cyclic-di-nucleotides have emerged as
promising vaccine adjuvants (Ebensen et al., 2007; Chen
et al., 2010; Libanova et al., 2010). In particular, it was
demonstrated that 3′ 5′-cyclic-di-adenosine monophosphate
(c-di-AMP) promotes the immune response in both human
immune cells as well as in mice models (Ebensen et al., 2017).
This metabolite is a bacterial second messenger involved in
different metabolic processes including potassium uptake, cell
turgor and cell wall homeostasis (Reuss et al., 2017; Commichau
et al., 2018). Furthermore, recent studies showed that c-di-AMP
has a strong mucosal adjuvant activity that potentiates both
humoral and cellular immune responses (Chen et al., 2010;
Ebensen et al., 2011). In mammals, c-di-AMP is an agonist of
the STimulator of INterferon Genes (STING) response, which
acts as an innate immune sensor of microbes leading to type
I interferon production (Lirussi et al., 2017). Moreover, several
investigations have shown that mucosal immunization with c-di-
AMP promotes a strong Th1 bias, a requisite for the control of
intracellular pathogens (Burdette et al., 2011). Recently it was
described that type I IFN is essential for c-di-AMP mediated
cross-presentation by a cathepsin independent and TAP and
proteasome dependent cytosolic antigen processing pathway,
indicating that type I IFN signaling is critical for cyclic di
nucleotides-mediated cross-presentation (Lirussi et al., 2017).
In this report we take advantage of the potential of c-di-
AMP as mucosal immunostimulator to develop a mucosal
vaccine prototype based on an engineered L. lactis carrying
genes encoding the cyclase enzyme responsible for c-di-AMP
synthesis (CdaA) (Reuss et al., 2017), as well as, a specifically
designed peptide derived from the trans-sialidase enzyme (TS),
a proved immunogenic antigen of the Trypanosoma cruzi
parasite, the etiological agent of Chagas disease (Nardy et al.,
2016). T. cruzi TS catalyzes the transfer of sialic acid from
the host glycoconjugates to the terminal β-galactopyranosyl
residues of mucin-like molecules on the cell surface of parasite
(Freire-de-Lima et al., 2015). TS is also involved in different
pathways leading to parasite infection and down-regulation of
the host immune response. In addition, this antigen is considered
nowadays one of the best candidates for the development of
prophylactic vaccines against T. cruzi (Bontempi et al., 2017).
In this study, we constructed a novel engineered L. lactis strain
able to produce simultaneously the TScf antigen and the c-di-
AMP adjuvant. Three successive oral immunizations with this
engineered L. lactis elicited a clear response against TScf. These
results suggest that oral formulations based on both c-di-AMP
and heterologous antigen-producing L. lactis strain could be
used as a new vaccine delivery system aiming to develop specific
immune protection.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Lactococcus strains were routinely grown in M17 medium
(Oxoid) supplemented with 0.5% (wt/vol) glucose (M17G) at
30◦C without shaking. Initial pH was adjusted to 7.0 or 5.5
with HCl when specified. Escherichia coli strains were used as
cloning host. Cultures of E. coli were grown aerobically in Luria
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Bertani medium (LB) at 37°C, and transformed as previously
described (Sambrook and Russell, 2001). Agar (1.5%) was added
to the medium when was required. Antibiotics were added
as selective agents when needed: 5 µg/ml erythromycin and
10 µg/ml chloramphenicol for L. lactis and 100 µg/ml ampicillin
or 150 µg/ml erythromycin for E. coli. Plasmids and bacterial
strains used in this study are listed in Table 1.
Trans-Sialidase Antigen Prediction and
TS Fragment Encoding Gene Synthesis
Full sequence of the trans-sialidase enzyme was analyzed in
order to predict T epitopes against H-2Kd MHC-I by using the
Propred I prediction server (Singh and Raghava, 2001). The gene
that encodes the selected fragment of TS (TScf) was synthetized
taking into account the codon usage of L. lactis MG1363 strain
and cloned in pUC57 by GenScript (United States).
DNA Manipulation and Construction of
Recombinant L. lactis Strains
cdaA was amplified by PCR using chromosomal DNA extracted
from L. lactis IL1403 as template and the pair of primers
IQ369 (ACGTAACCATATGTTGACCGACTTCAATC,
underlined nucleotides indicate the NdeI site) and IQ370
(GCTCTAGAAAGCTTTTATTTGCCATTTTTC, underlined
nucleotides indicate the XbaI site). The resulting fragment
was purified, digested with NdeI and XbaI and ligated into the
NdeI-SpeI sites of pBV153 vector, originating pIQ101 plasmid
(Figure 1A). This construction was transformed in E. coli
DH5α and the primary sequence of cdaA gene was checked
by sequencing (University of Maine, DNA sequencing Facility,
United States). Plasmid pIQ101 was then electroporated in
L. lactis cells as previously was described (Dornan and Collins,
1990) resulting in strain LL1 (Table 1).
L. lactis gdpP-defective strain was constructed by gene
deletion using the thermosensitive suicide plasmid pIQ095
(derived from vector pBVGh, Blancato and Magni, 2010).
This plasmid was constructed using E. coli EC101 as
host (Blancato and Magni, 2010). Oligonucleotides used
for the amplification of gdpP gene upstream region were
UJ5, AAACCATGGCCGTTTGGGCAATTGAAGACA and
UJ6, TTTAAGCTTATTAAAACGGATGACCCCAATTG
and for the downstream region were DJ7,
AAAAAGCTTATTATGGAGCAAATGGGTGGG and
DJ8, TTTCCATGGGCTTTTCTTTTTCCTTAGCTTTGG
(Figure 1C). Specific gene deletion was confirmed by PCR
and the following oligonucleotides: external region of gdpP:
EJ6, GGTTCTATGAAATTTAAAGCAGTGATTT and EJ7,
TTAGGCCTCGCTAATTTTGACTT; internal fragment
of gdpP IJ4, AAAATGCGAGCGATGACCAA and IJ5,
TABLE 1 | Plasmids and bacterial strains used in this study.
Strain or plasmid Description Reference
Plasmids
pNZ8048 Expression vector containing Pnis nisin -inducible promoter, CmR de Ruyter et al., 1996
pBV153 Expression vector derived from pBM01 containing chromosomal pH-controllable promoter region
Pcit and NdeI cloning site, CmR
Marelli and Magni, 2010
pBVGh Thermosensitive vector derivate of pWV01 for quick generation of gene deletion, EmR Blancato and Magni, 2010
pUC57-TScf pUC57 derived plasmid encoding codon optimized 6xhis tagged trans-sialidase fragment (TScf). This work
pNZ-TScf pNZ8048 derivative carrying the tscf gene under Pnis promoter. This work
pIQ095 pBVGh derivative plasmid carrying the upstream and downstream DNA fragments of L. lactis gdpP
for gene deletion, EmR
This work
pIQ101 pBV153 derivative plasmid carrying L. lactis cdaA gene under Pcit promoter, CmR This work
pIQ10-TS pBV153 derived plasmid carrying cdaA gene under Pcit promoter and trans-sialidase fragment
under Pnis promoter, CmR
This work
Strains
E. coli DH5-α. F- φ80d/lacZ1M15 1(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-, mK+) phoA supE44 λ- thi- 1
gyrA96 relA1
Hanahan, 1983
E. coli EC101 KanR supE thi 1(lacproAB) (F′ traD36 proAB lacIq Z1M15) repA. Law et al., 1995
L. lactis IL1403 Trp+ plasmid-free Bolotin et al., 2001
L. lactis NZ9000 L. lactis MG1363 containing nisRK genes integrated into pepN locus, plasmid free Kuipers et al., 1998
L. lactis NZ9000 clpP-htrA NZ9000 carrying clpP and htrA disruption, plasmid free Cortes-Perez et al., 2006
L. lactis LL0 L. lactis IL1403 carrying pBV153 vector This work
L. lactis LL1 L. lactis IL1403 carrying plasmid pIQ101 This work
L. lactis LL2 L. lactis IL1403 1gdpP1 This work
L. lactis LL3 NZ9000 clpP-htrA carrying pNZ8048 vector Cortes-Perez et al., 2006
L. lactis LL4 L. lactis NZ9000 strain harboring pNZ-TScf plasmid, for antigen expression This work
L. lactis LL5 NZ9000 clpP-htrA carrying plasmid pNZ-TScf This work
L. lactis LL6 NZ9000 clpP-htrA carrying plasmid pIQ101 This work
L. lactis LL7 NZ9000 clpP-htrA carrying plasmid pIQ10-TS This work
CmR and EmR indicate resistant to chloramphenicol and erythromycin, respectively.
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FIGURE 1 | Engineering of L. lactis strains with increased cytosolic c-di-AMP levels. (A) Schematic map of the recombinant plasmid pIQ101 carrying the membrane
lactococcal cdaA gene under the pH-controlled Pcit promoter. IQ369 and IQ370 oligonucleotides used for amplification: are indicated in the text. CdaA of L. lactis is
composed of three transmembrane segments (TMS) and one cytosolic cyclase domain (DAC domain). cat: gene encoding chloramphenicol acetyl transferase
conferring CmR phenotype. (B) Growth patterns of L. lactis IL1403 strain transformed with pBV153 vector (LL0 strain, indicated in circles) or pIQ101 (LL1 strain,
indicated by squares). Lactococcal cells were grown in M17G and monitored by OD600 measurements for 10 h at 30◦C. (C) Construction of the deficient gdpP
phosphodiesterase L. lactis strain. Primers indicated by arrows were used for deletion check, see details in the text and (Blancato and Magni, 2010). (D) c-di-AMP
intracellular levels of L. lactis strains. IL1403 derived strain transformed with pNZ8048 (LL0) or pIQ101 (LL1) and LL2 with a deletion in gdpP gene. pH 5.5 are
indicated in red bar and pH 7.0 in blue.
TTAATGGCTGTTCGACCGCT (Figure 1C; further details
described in Blancato and Magni (2010).
TScf encoding gene cloned in pUC57 was obtained from
digestion using NcoI and HindIII enzymes and subcloned
in pNZ8048 plasmid (de Ruyter et al., 1996). Plasmid
pNZ-TScf (Figure 2C) was electroporated into L. lactis
strains and positive clones were identified by colony
PCR using primers CGAGCATAATAAACGGCTCTG and
ATTGCCATTTCAATTGAACG and sequencing (University
of Maine, DNA sequencing Facility, United States) (Table 1).
Plasmid pIQ10-TS carrying both genes encoding tscf and
cdaA in single vector was constructed as follows: tscf under
control of Pnis promoter region was amplified by PCR
using pNZ-TScf as template and the pair of primers IQ696
(AAACTGCAGGTTGAAGAAGGTTTTTATATTACAGC,
underlined nucleotides indicate the PstI site) and IQ697
(TTTGTCGACGGTGGACAAATTTACATTAGTCTC,
underline indicate the SalI site). The resulting fragment
was purified, digested with PstI and SalI, and ligated into the
same sites of pIQ101 plasmid (Figure 4A). This construction was
transformed in E. coli DH5αand primary sequence was checked
by sequencing (University of Maine, DNA sequencing Facility,
United States). Plasmid pIQ10-TS was then electroporated in
L. lactis cells giving the strain LL7 (Table 1).
Protein Expression and TScf Purification
The His-tagged TScf protein in pNZ-TScf was overexpressed
in L. lactis NZ9000 clpP-htrA strain (Cortes-Perez et al., 2006)
(LL5 strain, Table 1). Cells were grown in 3 l of M17G broth
at 30°C to an OD600 = 0.5. Gene expression was induced with
5 ng/ml of nisin and the cells were further incubated for 3 h
(Figure 2D). Cells were then collected by centrifugation and
stored at -80°C. For protein purification, cells were resuspended
in lysis buffer (30 mM Tris–HCl pH 8.0, urea 8 M) and
were lysed with a mini-beadbeater-16 (Biospec, Bartlesville, OK,
United States) using 0.1 µm glass beads. The lysate was clarified
by centrifugation, then NaH2PO4 and imidazole were added to
a final concentration of 100 and 5 mM, respectively, pH was
adjusted to 8.0. The clarified lysate was run through a Ni2+-NTA
affinity column (Qiagen) and incubated at room temperature
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FIGURE 2 | Development of an optimized TS derived antigen. (A) Complete sequence of trans-sialidase protein(GenBank: PBJ79959.1). The selected fragment is
highlighted in purple and colored amino acids within this sequence indicate predicted T epitopes, underlined amino acids refer to overlapping epitopes. (B) Structure
modeling of whole TS (right) and the synthetic antigen (left) using PDB entry 1MS3 as template (according to Blancato et al., 2016); Epitopes T are indicated,
RFANHAFTL (pale red), IYNVGQVSI (cyan), VYSLVFARL (green) and VFARLVGEL (yellow). (C) Cloning representation of his6x-tscf in pNZ8048 derived plasmid. (D)
Expression check by SDS-PAGE (left) and Western blot analysis (right). L. lactis NZ9000 clpP-htrA transformed with pNZ8048 (strain LL3) or pNZ-TScf (strain LL5),
lactococcal cells were grown in M17G and induced at OD600 = 0.5. Nisin concentration and time are indicated in the figure. The band corresponding to Tscf is
indicated by an arrow. MWM: low-range molecular weight marker (Bio-Rad, Hercules, CA, United States).
for 1 h to allow binding. Then, the protein was refolded by
successive passaged in-column incubation with 50 mM Tris–HCl
pH 7.4, 500 mM NaCl, 5% glycerol buffer (buffer C) containing
decreasing concentrations of urea ranging from 6 to 0 M. The
column was washed with buffer C plus 25 mM imidazole and
the protein was eluted from the column in elution buffer (buffer
C with 500 mM imidazole). The purified protein was dialyzed
against PBS plus 5% glycerol; aliquots were kept at -80◦C.
Protein Extraction and Western Blot
Analysis
Protein samples were prepared from 5 ml of L. lactis cultures.
Cell pellets were washed once with 30 mM Tris–HCl pH 8.0,
150 mM NaCl. Next, bacterial cells were resuspended in lysis
buffer (30 mM Tris–HCl pH 8.0, Urea 8 M) and were lysed with
a mini-beadbeater-16 (Biospec, Bartlesville, OK, United States)
using 0.1 µm glass beads. Protein concentration was determined
by Lowry method using bovine serum albumin (BSA) as standard
(Lowry et al., 1951).
SDS-PAGE was used to analyze samples, loading 30 µg of
total protein per lane in the gels. Protein sizes were estimated
using low-range molecular weight marker (Bio-Rad, Hercules,
CA, United States). For western blot analysis, proteins were
transferred to nitrocellulose membranes using a mini-protean
2 cell unit (Bio-Rad, Hercules, CA, United States). Protein
transfer efficiency was assessed by staining with Ponceau red
S (Sigma, United States). TScf was detected with anti-his
polyclonal antibodies (Santa Cruz Biotechnology, United States)
at a 1:200 dilution. Alkaline phosphatase-conjugated goat anti-
rabbit immunoglobulin G (Bio-Rad, Hercules, CA, United States)
diluted 1:3000 was used as secondary antibody. P-nitroblue
tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indoyl
phosphate (BCIP) were used as substrates to detect phosphatase
activity.
Determination of c-di-AMP Intracellular
Levels
Twenty milliliter cultures of L. lactis were grown in M17G
medium supplemented with the corresponding antibiotics when
needed and the initial pH indicated in the Figure 1D. When
samples reached OD600 = 0.5, cells were harvested at 4°C and
5000 rpm and quickly frozen in liquid nitrogen. Two additional
samples of 1 ml were taken for normalization purposes. Samples
were collected and stored at -20°C until c-di-AMP extraction
was performed. For this, pellets were resuspended in 150 µl
of 2 mg/ml lysozyme in TE buffer and incubated for 30 min
at 25°C. Afterward, samples were frozen in liquid nitrogen
and boiled at 95°C for 10 min. First, an extraction with
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800 µl acetonitrile:methanol 1:1 was performed. Then, two
consecutive extractions with 200 µl acetonitrile:methanol:water
2:2:1 were performed. Supernatants were collected and dried in
a Speedvac at 40°C. Pellets were sent to Prof. Volkhard Kaever
from the Medizinische Hochschule, Hannover for c-di-AMP
quantification. Final data was normalized with respect to the
amount of protein present in the sample, determined via Lowry
assay (Lowry et al., 1951).
Mice and Animal Facility Conditions
BALB/c female mice, aged 6 weeks, were acquired and housed
at the animal facility of the CIPREB (Center for Research and
Production of Biological Reagents, School of Medicine, National
University of Rosario, Argentina). Mice were housed in HEPA-
ventilated racks, 21–22◦C and 68% of humidity. Animals had
free access to food and water and were maintained under a 12 h
light/dark period. All protocols for animal studies were approved
by the Bioethics and Animal Care and Use Committees according
to Institutional guidelines (Resolution N◦6698/2014).
Preparation of Live Bacterial Inoculum
and Immunization Protocol
Three liters of fresh M17G were inoculated with the strain of
interest and the corresponding antibiotics at an initial OD600
of 0.05. Antigen production (TScf) in strains L. lactis LL5 and
LL7 was induced at t0 by addition of nisin prior to inoculation,
concentration is described in each case Figures 3, 4. Synthesis
of the adjuvant c-di-AMP (strains LL1, LL6, and LL7 carrying
the cdaA gene under the promoter region Pcit) was induced by
culturing bacteria at initial pH of 5.5 (Marelli and Magni, 2010).
Growth was performed at 30°C without shaking until final OD600
reached 0.5.
In all cases, cells were harvested by centrifugation at 5000 rpm
and 4◦C. Pellets were then washed and resuspended in sterile PBS
to reach final concentrations in the order of 1× 109 CFU/100 µl.
Afterward, BALB/c female mice were used to evaluate the specific
anti-TS cellular immune response of the different engineered
L. lactis strains. Briefly, mice (n = 5 animals/group) were
immunized by oral route in three successive doses separated
by 2-week intervals. The bacterial dose administered was set
as a quantity of bacteria expressing 10 µg of TScf (0.3–
1 × 106 CFU/100 µl). Similar quantities of bacteria producing
only TScf, CdaA or carrying the vector were administrated by oral
gavage using a cannula in parallel groups (100 µl/mice). Taking
into account our previous experience on the high efficacy of TS
antigen to protect against T. cruzi infection when it is delivered
subcutaneously, we introduce in parallel a comparative group
of animals that were immunized subcutaneously with 10 µg of
purified TScf adjuvated with 3 µg of ISPA as a gold standard
or positive control group [Co(+)], being ISPA an ISCOMATRIX
type adjuvant (Bertona et al., 2017).
Delayed-Type Hypersensibility Response
in Mice
To test cellular response, mice were challenged with 5 µg of
purified TScf by intradermal injection in the right footpads
12 days after the last immunization. The thickness of hind
footpads was measured 48 h after the antigen injection with a
digital Vernier caliper. Results of the delayed hypersensitivity test
were expressed as the difference in thickness of footpads after and
before the inoculation.
Statistical Analyses
Data analysis were performed using non-parametric tests
(Kruskall-Wallis test for the analysis of k < 2 groups while
the Mann-Whitney test was employed to analyze differences
between two particular groups. All analyses were performed
using GraphPad Prisma 6.0 software (GraphPad, La Jolla, CA,
United States). The data were considered significant when
p < 0.05.
RESULTS
Construction of a L. lactis Strain With
High Cytoplasmic Concentration of
c-di-AMP
In order to increase the intracellular levels of c-di-AMP in L. lactis
different strategies were conducted. First, homologous expression
of cdaA, in charge of c-di-AMP synthesis in L. lactis (Reuss et al.,
2017) was performed. To do this, cdaA was amplified and cloned
in the pBV153 vector, resulting in plasmid pIQ101 (Figure 1A
and Table 1). pBV153 was developed in our laboratory and it
has the Pcit promoter upstream of the multiple cloning site,
leaving the expression of the gene of interest under pH regulation
(Marelli and Magni, 2010). pIQ101 plasmid was electroporated
in L. lactis IL1403, originating L. lactis cdaA+ (LL1, Table 1).
Phenotypic impact of the induction of cdaA expression was
evident on growth curves performed in the rich-medium M17G.
L. lactis cdaA+ needed approximately four additional hours
of growth to reach similar µmax and final biomass than the
control strain L. lactis pBV153 (LL0 strain) (Figure 1B and
Table 1). Changes in growth patterns were more evident in
presence of different stress factors. L. lactis cdaA+ showed a saline
hypersensitivity growth defect at 0.25 M NaCl or upon addition
of antibiotic compounds (Ampicillin 0.25 µg/ml, Penicillin
0.10 µg/ml, Vancomicyn 0.50 µg/ml), or Lysozyme 0.10 µg/ml
(Quintana, 2018). These results suggest that overproduction of
CdaA mediates an increment of the intracellular synthesis of c-di-
AMP that was previously related to the observed phenotypes in
L. lactis and other bacteria (Smith et al., 2012; Gundlach et al.,
2015; Rismondo et al., 2016; Quintana, 2018).
A second strategy used in order to increase c-di-AMP
intracellular concentrations was to inactivate gdpP. This gene
codes for the unique c-di-AMP phosphodiesterase reported in
L. lactis to be involved in the degradation of this compound
(Smith et al., 2012). The mutant strain where gdpP gene was
removed via homologous recombination was constructed using
the thermosensitive plasmid pIQ095 (Table 1 and Figure 1C).
Interestingly, the resulting L. lactis gdpP− mutant (LL2 strain,
Table 1) showed normal growth in M17G media. On the other
hand, growth parameters were reduced in the presence of the
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FIGURE 3 | Oral co-administration of L. lactis expressing TScf encoding gene and L. lactis overproducing c-di-AMP induce a specific cellular immune response.
(A) Schematic representation of recombinant L. lactis strains used in the experiment. LL1 (induced at pH 5.5 units) and LL3 and LL5 (induced with 5 ng/ml nisin).
(B) Oral immunization scheme. Three doses were administered with 15 days intervals. Footpad swelling was measured 48 h after the last immunization to determine
the degree of delayed-type hypersensitivity (n = 4–5 animals/group). (C) Immunization carried out by co-administration of LL1+LL5 shows a significant difference
with respect to LL5 as well as LL3 groups. (D) Morphological difference in footpad swelling in non-immunized mice (up) and LL1+LL5 group (down). NI:
non-immunized, Co (+): positive control group. Results are expressed as the difference in footpads thickness after and before the inoculation. ∗p < 0.05; 8p < 0.05
NI versus the rest of the groups. #p < 0.05 among Co (+) and LL5 and LL3.
β lactamic antibiotic penicillin, suggesting alteration in the
intracellular level of the c-di-AMP of the L. lactis gdpP− strain
(Quintana, 2018).
With the aim of determining the direct effect of cdaA
overexpression or gdpP disruption on the intracellular levels
of c-di-AMP, measures of its concentration were performed in
L. lactis cultures. Induction at low or neutral initial pH were
performed as previously described (Marelli and Magni, 2010).
c-di-AMP concentrations in L. lactis IL1403 wild type or L. lactis
pBV153 (LL0) strains were 27 ± 4 and 32 ± 2 ng per mg
of protein when initial pH values were set at 7.0 and 5.5,
respectively. On the other hand, c-di-AMP concentrations in
L. lactis cdaA+ (LL1) were 342 ± 89 and 675 ± 258 ng per mg
of protein at pH 7.0 and 5.5, respectively. As regards L. lactis
gdpP− (LL2), it showed only twice the concentration of c-di-
AMP (73 ± 6 ng per mg of protein) at pH 7.0 compared to
the wild type strain (Figure 1D). These results suggest that the
wild type growth phenotype of L. lactis gdpP− might derive
from the mild modification in cytosolic c-di-AMP levels in such
mutant. Also, they confirm that cdaA gene under Pcit control
was induced and generated the accumulation of cytosolic c-di-
AMP in L. lactis cdaA+. Thus, the later strain (LL1), growing at
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FIGURE 4 | Expression performance and specific immune response induced after oral immunization of L. lactis strain simultaneously expressing TScf encoding gene
and overproducing c-di-AMP. (A) The regulation systems of L. lactis NZ9000 clpP-htrA transformed with pIQ10-TS (strain LL7). The systems governing the
expression of the antigen tscf gene (under PnisA control) and cdaA gene (under PcitM control) are depicted. (B) Production of TScf in crude extracts of engineered
L. lactis strains. L. lactis NZ9000 clpP-htrA strain transformed with pNZ8048 (LL3), pNZ-TScf (LL5), or pIQ10-TS (LL7) was grown in M17G at initial pH 5.5 (induction
condition for PcitM). Nisin concentrations and OD600 used for induction are indicated in the figure. Cells were harvested at OD600 = 0.5 in all cases. Arrows indicate
TScf band, MWM: low-range molecular weight marker (Bio-Rad, Hercules, CA, United States). (C) Footpad testing. Strains LL3, LL5, LL6 (L. lactis NZ9000
clpP-htrA transformed with pIQ101), and LL7 were grown in M17G at initial pH 5.5 with 15 ng/ml nisin (induction condition for PcitM and PnisA, respectively). The
immunization protocol consisted in 3 doses of each strain separated by 15 days intervals. Fifteen days after last immunization, the specific cellular response was
analyzed by DHT test (n = 4–5 animals/group). Results are expressed as the difference in footpad thickness before and 48 h after TS inoculation. (D) Morphological
differences in footpads swelling in non-immunized mice (NI) and LL7 group. ∗p < 0.05; 8p < 0.05 NI versus the rest of the groups. #p < 0.05 among positive control
group -Co(+)- and LL5, LL3, and LL6.
initial pH value of 5.5, where the highest concentrations of c-di-
AMP were measured, was selected for its evaluation as immune
stimulator.
Antigen Design and TScf Gene
Expression in L. lactis
In order to ensure its production in L. lactis, the smallest possible
protein size of the TS with the highest presence of epitopes able
to trigger a TS-specific immune response was selected. Protein
regions with the highest density Class I–Restricted T Cell epitopes
were selected taking into account that T cruzi is an intracellular
parasite, and therefore, an immune T cell response is needed
to protect against this infection. Since BALB/c mice was our
animal model, T epitopes against H-2Kd MHC-I were predicted
using the tools Propred I (Singh and Raghava, 2001). Four out
of the seven epitopes identified by Propred I are localized in the
central region of the protein ranging from amino acid 326–496
(Figure 2A). Interestingly, the predicted IYNVGQVSI epitope,
located in this region, was described as the main MHC-I T-cell
epitope that provides protection against T. cruzi infections in
BALB/c mice (Martin et al., 2006; Rosenberg et al., 2010; Eickhoff
et al., 2011). Based on epitope analyzes, the fragment that covers
the amino acid 326–496 was selected for immune response
studies and called TScf (Figure 2).
A TScf encoding gene was synthetized optimizing its codon
usage for L. lactis and incorporating a stop codon, the NcoI and
HindIII restriction sites required for cloning, and 6xHis encoding
codons at 5′ to allow detection by western blot (GenScript,
Township, NJ, United States). The synthetic gene was subcloned
into pNZ8048, resulting in vector pNZ-TScf (Figure 2C) that
encodes TScf under the transcriptional control of Pnis promoter.
pNZ-TScf was electroporated in L. lactis NZ9000 originating
strain LL4 (Table 1). However, no production of TScf was
detected in this host.
An alternative L. lactis NZ9000 derived strain used for high
level of heterologous proteins production is L. lactis NZ9000
clpP-htrA strain which is deficient for the two lactococcal major
proteases (Cortes-Perez et al., 2006). Then, NZ9000 clpP-htrA
strain was transformed with pNZ-TScf, resulting in LL5 strain
(Table 1). LL5 showed stable overexpression of the TScf encoding
gene. As shown in Figure 2D, antigen production was barely
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detectable after 1 h of induction with 5 or 50 ng/ml of nisin
but an overproduced band was observed at 3 h with coomasie
blue staining. This was confirmed by western blot using anti-his
antibodies (Figure 2D) whereas protein identity was determined
by Mass spectrometry (MS/MS).
Immune Response Induced by Mucosal
Co-administration of L. lactis Expressing
TScf Encoding Gene and L. lactis
Overproducing c-di-AMP
Once obtained a strain of L. lactis expressing TScf encoding
gene and a strain producing high amounts of c-di-AMP, our
first aim was to evaluate the potential effectiveness of their co-
administration, as proof of concept for the development of a new
prototype of mucosal vaccines (Figure 3A). Three successive oral
immunizations were performed (Figure 3B). The studied groups
were: (i) NI (non-immunized group -NI-), mice that received
only PBS buffer; (ii) LL1+LL5 group, mice co-administered with
both induced systems in separated strains, c-di-AMP adjuvant
and TScf antigen, respectively; (iii) LL5 group, mice that received
L. lactis expressing the TScf antigen (Figure 3). In addition,
L. lactis clpP-htrA harboring the pNZ8048 vector (LL3 strain)
was also orally administered as control (LL3 group), and finally
a group of mice was simultaneously immunized by subcutaneous
way with purified TScf adjuvanted with ISPA as a positive
control group -Co(+)-, being ISPA a cage like particle adjuvant
developed by Dr. Marcipar et al. (Bertona et al., 2017).
As shown in Figure 3C, 15 days after the last immunization,
all groups [including the Co(+) group] was footpad testing. After
48 h, DHT showed that L. lactis LL1+LL5 immunized group
elicited a similar magnitude of footpad thickness than Co(+)
group. In addition, the TS-specific response elicited by the LL7
group were more evident than in the LL5 group and even greater
when compared to NI and LL3 groups. These results support that
TScf sequence contains MHC-I T-cell epitopes, but also suggest
that orally administered L. lactis over-expressing cdaA gene (LL1)
could be used as immune stimulator of the response against
T. cruzi.
Engineered L. lactis Co-producing
Antigen and Adjuvant for Mucosal
Administration
In order to construct a fully integrated mucosal vaccine
prototype, a single vector carrying both genes encoding the TScf
antigen and the CdaA enzyme was designed (Figure 4). For
this, the TScf encoding region from pNZ-TScf was amplified,
including the Pnis promoter and the terminator (Figure 2A). The
fragment was subcloned in the PstI-SalI restriction sites of vector
pIQ101 (Table 1). This plasmid was electroporated in L. lactis
clpP-htrA, and the resulting cdaA+-tscf+ strain was named LL7
(Figure 4A). Then, tscf expression under conditions previously
proven to increase c-di-AMP levels in L. lactis was evaluated
(strain LL5). Hence, L. lactis cdaA+-tscf+ (LL7) was grown in
M17G medium at initial pH value of 5.5 and tscf expression was
induced by adding nisin at the initial time, prior to inoculation
(OD600 = 0.05) or at OD600 = 0.3. As shown in the Figure 4B,
L. lactis cdaA+-tscf+ overproduces TScf when 15 ng/ml nisin
were added to the media independently of the OD of induction.
On the other hand, overproduction of TScf in L. lactis cdaA+ was
only detected when nisin was added at OD600 = 0.05 (Figure 4B).
To analyze the in vivo cell-mediated immune response elicited
by L. lactis co-producing TScf and CdaA (LL7), a similar
scheme of three successive oral immunizations was performed,
as previously described in Figure 3B. L. lactis strains expressing
the TScf encoding gene (LL5), harboring the vector pNZ8048
(LL3) and cdaA (LL6) were also included. Negative and positive
control groups were also simultaneously evaluated [NI and
Co(+) groups, respectively] (Figure 4C). Fifteen days after the
last immunization, the degree of inflammation after 48 h of
intradermal inoculation of purified TScf was tested (Figure 4D).
Noteworthy, only LL7 group elicited a TS-specific cellular
response of similar magnitude than Co(+). Moreover, was
observed a clear increase in the footpad thickness in LL7 group
compared to NI or LL5 groups. In addition, the cellular response
noticed in LL3 was smaller than that registered in LL7, although
it did not reach statistical significance (p < 0.06). Moreover, in
this case LL5 and LL3 did not differ among themselves. These
results indicate that immunization with L. lactis cdaA+-tscf+ was
effective for sensitizing against TScf.
DISCUSSION
Vaccination is one of the most important interventions in the
field of public health. Molecular techniques opened the possibility
to develop vaccines using purified fragments of proteins and
recombinant antigens. Nevertheless, these fragments of antigen
usually show poorly immunogenic properties and the use of
adjuvants becomes necessary to potentiate the specific immune
response. Since several pathogens used diverse mucosal surfaces
as an entry portal, the development of innovative mucosal
vaccines is a priority challenge, even more if the ability of this type
of vaccine to elicit both mucosal and systemic immune protection
is considered.
On the other hand, L. lactis is a good candidate for the
delivery of biologically active immunomodulatory proteins or
the production of active biological compounds (Wells and
Mercenier, 2008). Also, L. lactis safety is well established and this
microorganism offers a substantial potential as a delivery vector
system for vaccines, particularly because it can be administrated
by diverse mucosal routes like oral, nasal or intravaginal, and
it survives the passage through the gastrointestinal tract as
well (Wells and Mercenier, 2008). Here we describe first a live
vaccine prototype composed of two strains that showed to elicit
a clear TS-specific cell-mediated immune response. One strain
(L. lactis LL1) of the prototype serves as immune stimulator
overproducing the adjuvant c-di-AMP more than 19 times above
wild type levels in response to medium acidification (Figure 1D).
A second antigenic strain (L. lactis LL5) overproduces the
TScf antigen under control of a nisin inducible expression
system. A similar bipartite strategy was used successfully in
the development of an intra-nasal vaccine against the human
papilloma virus, where one strain expressed the virus antigen and
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another IL-12 as an immunostimulatory molecule (Bermudez-
Humaran et al., 2003). Noteworthy, both approaches evoked
an evident cellular response, which likely contribute to the
specific Th1-immune response. Moreover, an analogous strategy
was also used for desensitization in an experimental allergic
airway disease model (Cortes-Perez et al., 2006, 2007). Despite
DHT as an estimation of TS-specific cellular response has same
limitations (i.e., does not allow to recognize the T subpopulations
involved in the specific response or the cytokines contributing
in such reaction), the DHT assay continue to be one of the
most rapid and available tests for the evaluation of this type
of response during the screening of vaccine prototypes. As we
have previously shown in other immunization schemes using TS
(Bontempi et al., 2015, 2017; Bertona et al., 2017), it is expected
that IFN-γ be one of the cytokines involved in this type of
reaction.
In this work, we also showed for the first time that a single
L. lactis strain producing both the c-di-AMP adjuvant and a
heterologous antigen (TScf), was capable to elicit a better specific
immune response compared to a L. lactis strain producing only
the antigen. The co-existence of both molecules in the same
strain of L. lactis, not only may favor the development of a
specific immune response (by exposing immunocompetent cells
to both molecules at the same time), but it can help as well to
reduce costs for the implementation of vaccination programs
in developing countries. In fact, other cases were reported,
where one-strain strategies were used, involving L. lactis strains
expressing a fusion protein of two antigens or an antigen and
the peptidic IL-2 adjuvant (Zhang et al., 2014; Beck et al.,
2017). Interestingly, one-strain vaccine prototypes based on a
L. lactis that overproduced adjuvants could be used or combined
with other antigens enabling systematic research of a variety of
antigens.
c-di-AMP exerts its adjuvant effect triggering a balanced
Th1/Th2/Th17 response and a strong IFN-type I production via
the STING-TBK1-IRF3 cascade (Burdette et al., 2011; Burdette
and Vance, 2013). Very promising results were obtained when
c-di-AMP was assessed as adjuvant in different prototypes of
mucosal vaccines against different viruses and bacteria (Sanchez
et al., 2014; Landi et al., 2017; Schulze et al., 2017). Particularly,
this adjuvant has also been used in previous studies for the design
and experimental assessment of subunit vaccines formulations
against T. cruzi (Matos et al., 2017; Sanchez Alberti et al.,
2017). In these studies, recombinant T. cruzi antigens were
formulated together with c-di-AMP and were administered
nasally, obtaining an immune response that allowed protection
after the challenge with the parasite. Moreover, using the Tc52
T. cruzi antigen, Matos and colleagues described a better adjuvant
ability of c-di-AMP in comparison with CpG, one of the
most potent adjuvants for the development of vaccines against
intracellular microorganisms (Matos et al., 2017). Reinforcing
these data, our results also show that an engineered L. lactis that
overexpresses c-di-AMP and a TS fragment could result in an
effective vaccine for Chagas disease.
Nowadays, c-di-AMP is only produced by expensive and
laborious procedures (Zheng et al., 2013). Engineering of L. lactis
overproducing c-di-AMP can solve this problem, allowing to
reach adequate quantities at mucosal level. However, the design
of a L. lactis strain with high intracellular concentration of
c-di-AMP is a rewarding but also a daunting task due the fact
that unbalanced intracellular levels of c-di-AMP might prevent
or hinder L. lactis growth. In fact, during the design and
evaluation of the c-di-AMP overproducer L. lactis strain, several
combinations of promoters with different strengths (Pnis, Pcit),
cdaA homologs (from E. faecalis or L. lactis), and hosts with
different genetic backgrounds (wild type, htrA− clpP−, or gdpP−)
were evaluated (not shown). Remarkably, in the present study
the objective to obtain a c-di-AMP overproducer L. lactis strain
with immune stimulatory properties was fulfilled. Nevertheless,
further studies should be performed to broaden the knowledge
regarding the regulation of c-di-AMP synthesis and degradation,
as well as its role in the physiology of L. lactis. This will open new
opportunities in the development of oral and mucosal vaccines.
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